

Economic analysis using base-case estimates

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.074	0.780	0.779
HF-related hospitalisation HR	1.000	1.045	0.778	0.966
All-cause hospitalisation HR	1.000	1.173	0.977	0.761
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	71.45	75.34	75.38
5 years (%)	33.75	33.43	35.25	35.27
Life expectancy over 30 years (years)	4.71	4.67	4.91	4.91
Difference in life expectancy vs usual care (years)	0.00	-0.04	0.20	0.20
Cost results (£)				
Discounted cost of usual care	491	343	362	362
Discounted cost of treatment	0	632	978	730
Discounted cost of HF-related hospitalisations	4187	4169	4257	4348
Discounted cost of other hospitalisations	3800	3858	4007	3803
Total costs	8478	9001	9604	9243
Difference in costs from usual care (£)				
Discounted cost of usual care	0	-148	-129	-129
Discounted cost of treatment	0	632	978	730
Discounted cost of HF-related hospitalisations	0	-19	70	161
Discounted cost of other hospitalisations	0	57	207	3
Total difference in costs	0	523	1126	765
Overall cost rank (1 = lowest cost)	1	2	4	3
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5509	2.6834	2.6848
HF-related hospitalisation decrement	-0.1611	-0.1604	-0.1638	-0.1673
Total discounted QALYs	2.4137	2.3905	2.5196	2.5175
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	-0.0239	0.1086	0.1100
HF-related hospitalisation decrement	0.0000	0.0007	-0.0027	-0.0062

	Usual care	STS HM	STS HH	TM during office hours
Total difference in discounted QALYs	0.0000	-0.0232	0.1059	0.1038
Total discounted QALYs rank (1 = highest)	3	4	1	2
Probabilistic ICER vs usual care (£/QALY)		Dominated	10,629	7367
Probabilistic sequential ICER (£/QALY)		Dominated	170,629 ^a	7367
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	2	17	31	50
Expected total costs from PSA (£)	8478	9001	9604	9243
Expected total QALYs from PSA	2.4137	2.3905	2.5196	2.5175
Expected net benefit from PSA (£)	39,795	38,809	40,788	41,107
Difference from usual care costs (£)	0	523	1126	765
Difference from usual care QALYs	0.0000	-0.0232	0.1059	0.1038
Difference from usual care net benefit (£)	0	-986.75	993	1311
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	707			
Population EVPI (£)	38,728,537			

^a Last strategy in the cost-effectiveness frontier.

Economic analysis using data from predictive distributions

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.180	0.849	0.843
HF-related hospitalisation HR	1.000	1.063	0.790	0.982
All-cause hospitalisation HR	1.000	1.302	1.074	0.835
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	70.61	74.58	74.66
5 years (%)	33.75	33.04	34.89	34.93
Life expectancy over 30 years (years)	4.710	4.614	4.862	4.867
Difference in life expectancy vs usual care (years)	-	-0.100	0.151	0.157
Cost results (£)				
Discounted cost of usual care	491	339	358	359
Discounted cost of treatment	0	627	972	726
Discounted cost of HF-related hospitalisations	4187	4130	4221	4316
Discounted cost of other hospitalisations	3800	3869	4023	3811
Total costs	8478	8965	9574	9211

	Usual care	STS HM	STS HH	TM during office hours
<i>Difference in costs from usual care (£)</i>				
Discounted cost of usual care	0	-152	-132	-132
Discounted cost of treatment	0	627	972	726
Discounted cost of HF-related hospitalisations	0	-57	33	129
Discounted cost of other hospitalisations	0	69	223	11
Total difference in costs	0	487	1096	733
Overall cost rank (1 = lowest cost)	1	2	4	3
<i>Discounted QALY results</i>				
QALYs with no hospitalisation decrement	2.5748	2.5223	2.6575	2.6605
HF-related hospitalisation decrement	-0.1611	-0.1589	-0.1624	-0.1661
Total discounted QALYs	2.4137	2.3633	2.4950	2.4944
<i>Difference in QALYs from usual care</i>				
QALYs with no hospitalisation decrement	0.0000	-0.0525	0.0827	0.0857
HF-related hospitalisation decrement	0.0000	0.0022	-0.0013	-0.0050
Total difference in discounted QALYs	0.0000	-0.0504	0.0814	0.0808
Total discounted QALYs rank (1 = highest)	3	4	1	2
Probabilistic ICER vs usual care (£/QALY)		Dominated	13,473	9080
Probabilistic sequential ICER (£/QALY)		Dominated	605,112 ^a	9080
<i>Uncertainty analyses using net benefit at £20,000 per QALY</i>				
Probability that strategy is most cost-effective (%)	6	18	33	44
Expected total costs from PSA (£)	8478	8965	9574	9211
Expected total QALYs from PSA	2.4137	2.3633	2.4950	2.4944
Expected net benefit from PSA (£)	39,795	38,301	40,327	40,677
Difference from usual care costs (£)	0	487	1096	733
Difference from usual care QALYs	0.0000	-0.0504	0.0814	0.0808
Difference from usual care net benefit (£)	0	-1494.07	531	882
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	1702			
Population EVPI (£)	93,233,339			

^a Last strategy in the cost-effectiveness frontier.

Economic analysis using data excluding the Home-HF study⁶⁷

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.007	0.757	0.627
HF-related hospitalisation HR	1.000	1.042	0.766	0.872
All-cause hospitalisation HR	1.000	1.134	0.969	0.678
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	72.14	75.67	77.63
5 years (%)	33.75	33.75	35.40	36.32
Life expectancy over 30 years (years)	4.710	4.710	4.930	5.052
Difference in life expectancy vs usual care (years)	–	–0.0003	0.2200	0.3420
Cost results (£)				
Discounted cost of usual care	491	346	363	373
Discounted cost of treatment	0	635	981	742
Discounted cost of HF-related hospitalisations	4187	4206	4269	4426
Discounted cost of other hospitalisations	3800	3873	4021	3879
Total costs	8478	9060	9635	9420
Difference in costs from usual care (£)				
Discounted cost of usual care	0	–144	–127	–118
Discounted cost of treatment	0	635	981	742
Discounted cost of HF-related hospitalisations	0	18	82	239
Discounted cost of other hospitalisations	0	73	221	79
Total difference in costs	0	582	1157	942
Overall cost rank (1 = lowest cost)	1	2	4	3
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5747	2.6949	2.7612
HF-related hospitalisation decrement	–0.1611	–0.1619	–0.1643	–0.1703
Total discounted QALYs	2.4137	2.4128	2.5306	2.5908
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	–0.0002	0.1200	0.1864
HF-related hospitalisation decrement	0.0000	–0.0007	–0.0032	–0.0092
Total difference in discounted QALYs	0.0000	–0.0009	0.1169	0.1772
Total discounted QALYs rank (1 = highest)	3	4	2	1
Probabilistic ICER vs usual care (£/QALY)		Dominated	9897	5315
Probabilistic sequential ICER (£/QALY)		Dominated	Extendedly dominated	5315 ^a

	Usual care	STS HM	STS HH	TM during office hours
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	0	4	9	87
Expected total costs from PSA (£)	8478	9060	9635	9420
Expected total QALYs from PSA	2.4137	2.4128	2.5306	2.5908
Expected net benefit from PSA (£)	39,795	39,196	40,976	42,397
Difference from usual care costs (£)	0	582	1157	942
Difference from usual care QALYs	0.0000	-0.0009	0.1169	0.1772
Difference from usual care net benefit (£)	0	-599.54	1181	2602
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	100			
Population EVPI (£)	5,477,869			
a Last strategy in the cost-effectiveness frontier.				

Economic analysis using data from predictive distributions excluding the Home-HF study⁶⁷

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.032	0.776	0.642
HF-related hospitalisation HR	1.000	1.058	0.778	0.883
All-cause hospitalisation HR	1.000	1.235	1.048	0.731
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	71.89	75.44	77.44
5 years (%)	33.75	33.63	35.30	36.23
Life expectancy over 30 years (years)	4.71	4.69	4.92	5.04
Difference in life expectancy vs usual care (years)	0.00	-0.02	0.21	0.33
Cost results (£)				
Discounted cost of usual care	491	345	362	372
Discounted cost of treatment	0	634	979	741
Discounted cost of HF-related hospitalisations	4187	4200	4262	4422
Discounted cost of other hospitalisations	3800	3909	4055	3901
Total costs	8478	9087	9658	9435

	Usual care	STS HM	STS HH	TM during office hours
<i>Difference in costs from usual care (£)</i>				
Discounted cost of usual care	0	-145	-128	-119
Discounted cost of treatment	0	634	979	741
Discounted cost of HF-related hospitalisations	0	12	75	234
Discounted cost of other hospitalisations	0	108	255	101
Total difference in costs	0	609	1180	957
Overall cost rank (1 = lowest cost)	1	2	4	3
<i>Discounted QALY results</i>				
QALYs with no hospitalisation decrement	2.5748	2.5659	2.6870	2.7548
HF-related hospitalisation decrement	-0.1611	-0.1616	-0.1640	-0.1701
Total discounted QALYs	2.4137	2.4043	2.5230	2.5847
<i>Difference in QALYs from usual care</i>				
QALYs with no hospitalisation decrement	0.0000	-0.0089	0.1122	0.1800
HF-related hospitalisation decrement	0.0000	-0.0004	-0.0029	-0.0090
Total difference in discounted QALYs	0.0000	-0.0093	0.1093	0.1710
Total discounted QALYs rank (1 = highest)	3	4	2	1
Probabilistic ICER vs usual care (£/QALY)		Dominated	10,798	5595
Probabilistic sequential ICER (£/QALY)		Dominated	Extendedly dominated	5595 ^a
<i>Uncertainty analyses using net benefit at £20,000 per QALY</i>				
Probability that strategy is most cost-effective (%)	1	6	16	77
Expected total costs from PSA (£)	8478	9087	9658	9435
Expected total QALYs from PSA	2.4137	2.4043	2.5230	2.5847
Expected net benefit from PSA (£)	39,795	39,000	40,801	42,259
Difference from usual care costs (£)	0	609	1180	957
Difference from usual care QALYs	0.0000	-0.0093	0.1093	0.1710
Difference from usual care net benefit (£)	0	-795.73	1006	2463
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	353			
Population EVPI (£)	19,336,879			
<i>a Last strategy in the cost-effectiveness frontier.</i>				